Conditions: Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive Philadelphia Chromosome Positive Recurrent Acute Lymphoblastic Leukemia Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive Refractory Acute Lymphoblastic Leukemia Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive t(9;22)
Allocation: NON_RANDOMIZED | Intervention model: PARALLEL
Enrollment: 9
Healthy volunteers: no

Brief summary:
This phase I/II trial studies the best dose of venetoclax when given together with ponatinib and dexamethasone and to see how well they work in treating participants with Philadelphia chromosome or BCR-ABL positive acute lymphoblastic leukemia or chronic myelogenous leukemia that has come back or does not respond to treatment. Drugs used in chemotherapy, such as venetoclax and dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Ponatinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving venetoclax, ponatinib, and dexamethasone may work better in treating participants with acute lymphoblastic leukemia or chronic myelogenous leukemia.

Detailed description:
PRIMARY OBJECTIVES:

I. To determine the maximum tolerated dose (MTD) of venetoclax, ponatinib, and dexamethasone in patients with relapsed/refractory Philadelphia positive (Ph+) acute lymphoblastic leukemia (ALL) or lymphoid blastic phase (BP)-chronic myelogenous leukemia (CML). (Phase I) II. To determine the efficacy of the regimen, as defined by the rate of complete remission (CR) or CR with incomplete count recovery (CRi). (Phase II)

SECONDARY OBJECTIVES:

I. To determine efficacy outcomes, including rate of minimal residual disease negativity by polymerase chain reaction (PCR) for BCR-ABL1 transcripts, median relapse-free survival (RFS), and median overall survival (OS).

II. To determine the proportion of patients proceeding to allogeneic stem cell transplant (ASCT).

III. To preliminarily determine the safety of the combination regimen.

EXPLORATORY OBJECTIVES:

I. To evaluate the effect of single-agent ponatinib on apoptotic proteins and Bcl-2 dependency.

II. To correlate apoptotic protein expression and Bcl-2 dependency on response and resistance to the combination regimen.

III. To assess impact of baseline genomics on outcomes with the combination regimen.

OUTLINE: This is a phase I, dose-escalation study of venetoclax followed by a phase II study.

INDUCTION (COURSE 1): Participants who have not received ponatinib within 2 weeks of the anticipated start date receive ponatinib orally (PO) daily on days 1-35, venetoclax PO daily on days 8-35, and dexamethasone PO or intravenously (IV) over 15 minutes on days 8-11. Participants who have received ponatinib within 2 weeks of the anticipated start date receive ponatinib PO and venetoclax PO daily on days 1-28 and dexamethasone PO or IV over 15 minutes on days 1-4. Participants with CD20 expression receive rituximab IV over 2-6 hours on days 14 and 21 at the discretion of the treating physician after the maximum dose of venetoclax has been reached.

CONSOLIDATION (COURSES 2-4): Participants receive ponatinib PO and venetoclax PO daily on days 1-28 and dexamethasone PO or IV over 15 minutes on days 1-4. Participants with CD20 expression receive rituximab IV over 2-6 hours for up to 2 doses each course at the discretion of the treating physician after the maximum dose of venetoclax has been reached. Treatment repeats every 28 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.

MAINTENANCE (COURSES 5+): Participants receive ponatinib PO and venetoclax PO daily on days 1-28 and dexamethasone PO or IV over 15 minutes on days 1-4. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity. Participants achieving remission undergo ASCT at the discretion of the treating physician.

After completion of study treatment, participants are followed up at 30 days.

Arms:
arm 1: The regimen consists of 4 cycles of induction/consolidation followed by up to 2 years of maintenance therapy for responding patients. arm 2: The regimen consists of 4 cycles of induction/consolidation followed by up to 2 years of maintenance therapy for responding patients. arm 3: Participants in Phase II will receive the dose that was determined to be the Maximum Tolerated Dose (MDT) found in the Phase I portion of the study. The regimen consists of 4 cycles of induction/consolidation followed by up to 2 years of maintenance therapy for responding patients.

Interventions: intervention 1: Dexamethasone intervention 2: Ponatinib Hydrochloride intervention 3: Rituximab intervention 4: Venetoclax
Intervention descriptions: intervention 1: Given PO or IV intervention 2: Given PO intervention 3: Given IV intervention 4: Given PO

Protocol document:
Prot_SAP_001.pdf: 
2017-0313 
August 11, 2020 
Version 4 
1 
MD Anderson IND Sponsor Cover Sheet 
Protocol ID 
2017‐0313 
Protocol Title 
A Phase I/II Study of the Combination of Venetoclax, Ponatinib and 
Corticosteroids in Patients with Relapsed or Refractory Philadelphia 
Chromosome‐Positive Acute Lymphoblastic Leukemia and Lymphoid 
Blast Phase Chronic Myelogenous Leukemia 
Protocol Phase 
I/II 
Protocol Version 
4 
Version Date 
August 11, 2020 
Protocol PI 
Farhad Ravandi, MD 
Nicholas Short, MD 
Department 
Leukemia 
IND Sponsor 
MD Anderson Cancer Center 
IND # 
138929 
A Phase I/II Study of the Combination of Venetoclax, 
Ponatinib and Corticosteroids in Patients with Relapsed or 
Refractory Philadelphia Chromosome-Positive Acute 
Lymphoblastic Leukemia and Lymphoid Blast Phase Chronic 
Myelogenous Leukemia 
Principal Investigator: 
Farhad Ravandi, MD 
Department of Leukemia, 
University of Texas M D Anderson Cancer Center 


2017-0313 
August 11, 2020 
Version 4 
2 
 
 
1515 Holcombe Boulevard Unit 428 
Houston, Texas 77030 
Tel – 713-745-0394 
E-mail – fravandi@mdanderson.org 
 
 
Principal Investigator: 
 
Nicholas Short, MD 
Department of Leukemia, 
University of Texas M D Anderson Cancer Center 
1515 Holcombe Boulevard Unit 428 
Houston, Texas 77030 
Tel – 713-563-4485 
E-mail – nshort@mdanderson.org 
 
 
 
 
TABLE OF CONTENTS 
1. 
INTRODUCTION ....................................................................... 2 
2. 
STUDY OBJECTIVES AND ENDPOINTS ................................ 4 
3. 
SELECTION OF PATIENTS ..................................................... 4 
3.1 Inclusion Criteria ..................................................................... 4 
3.2 Exclusion Criteria .................................................................... 5 
4. 
TREATMENT OF SUBJECTS .................................................. 6 
5. 
CONCOMITANT MEDICATIONS ............................................ 11 
6. 
STUDY PROCEDURES .......................................................... 12 
7. 
EFFICACY AND SAFETY ASSESSMENTS ........................... 13 
8. 
REPORTING REQUIREMENTS ............................................. 14 
9. 
OUTSIDE PHYSICIAN PARTICIPATION ................................ 16 


2017-0313 
August 11, 2020 
Version 4 
3 
 
 
10. 
STATISTICAL METHODS ...................................................... 17 
11. 
REFERENCES ....................................................................... 17 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1. 
INTRODUCTION 
 
Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL): Ph+ ALL is an 
aggressive subtype of ALL characterized by the presence of the BCR-ABL1 gene fusion.1 
Historically, the outcomes of patients with Ph+ ALL were dismal, with a 3-year disease-free 
survival rate of <15%.2 However, with the incorporation of tyrosine kinase inhibitors (TKIs) into 
chemotherapy-based treatment regimens, survival rates of 30-80% have been achieved, with 
improved long-term survival seen in patients receiving later-generation TKIs.3-5 These TKIs target 
the aberrant Bcr-Abl1 protein, which is the primary driver of proliferation and survival of the Ph+ 
leukemic cells. With the combination of chemotherapy and a TKI, complete remission (CR) rates 
>90% can be achieved.4-7 Despite this high CR rate seen with TKI and chemotherapy 
combination regimens, many patients subsequently relapse; for these patients, outcomes are 
dismal and there is no clear standard of care. Recent evidence suggests that the bispecific T-cell 
engaging antibody, blinatumomab, has significant antileukemic efficacy for these patients.8 
However, even with this promising treatment, the overall response rate is only 36% and the 
median OS is approximately 7 months. Therefore, novel treatment options are needed for 
patients with Ph+ ALL who are refractory or relapse after initial treatment. 
Ponatinib: Ponatinib is a later-generation TKI that is capable of inhibiting the T315I BCR-ABL1 
kinase mutation, which commonly arises during treatment with other TKIs such as imatinib or 
dasatinib. In the phase II PACE trial of single-agent ponatinib in patients with relapsed/refractory 
Ph+ leukemias, ponatinib resulted in major hematologic response in 41% of patients with Ph+ 
ALL. However, the vast majority of patients relapsed, and the 1-year progression-free survival 
was only 7%. These results demonstrate that ponatinib has activity in relapsed and TKI-resistant 
Ph+ ALL, although as a single agent it does not appear to produce durable responses. In 
contrast, when combined with hyper-CVAD chemotherapy in patients with newly diagnosed Ph+ 
ALL, the ponatinib-containing regimen resulted in a CR rate of 100% with 2-year event-free 


2017-0313 
August 11, 2020 
Version 4 
4 
 
 
survival (EFS) and overall survival (OS) rates of 81% and 80%, respectively. Ponatinib can be 
associated with cardiovascular toxicity, including arterial and thromboembolic events; however, 
using risk-adapted dosing schedule of ponatinib may reduce this risk. Historical comparisons 
suggest the results achieved with the combination of hyper-CVAD plus ponatinib may be superior 
to those achieved with hyper-CVAD plus dasatinib. 
 
Venetoclax: Venetoclax (formerly ABT-199/GDC-0199) is a potent, selective and orally 
bioavailable small molecule BCL-2 inhibitor that has shown promising anti-leukemia activity in 
patients with relapsed or refractory chronic lymphocytic leukemia (CLL) as monotherapy and 
modest single agent activity in select subtypes of acute myeloid leukemia12-14; venetoclax is 
currently FDA approved for the treatment of patients with CLL with del(17)(p13.1) by interphase 
cytogenetics who have received at least one prior therapy. For patients with AML, combination 
therapy with venetoclax and other agents appears to be more efficacious that venetoclax 
monotherapy.15 BCL-2 is an anti-apoptotic protein that is over-expressed in many hematologic 
malignancies and is associated with tumor initiation, disease progression and drug resistance.16 
BCL-2 mRNA is highly expressed in multiple subtypes of ALL compared with normal pre-B 
controls.17 Recent reports demonstrated that primary B-lineage ALL cells each express high 
levels of BCL-2 and exhibit significant sensitivity to BCL-2 inhibition by venetoclax, resulting in 
rapid apoptotic cell death.18 Specifically, Ph+ ALL appears to be dependent on BCL-2 for 
survival; consequently, BCL-2 inhibition has been shown to result in apoptosis of Ph+ ALL cell 
lines.19 
Rationale for Combination of Ponatinib and Venetoclax: The combination of venetoclax and 
targeted BCR-ABL1 TKIs has been explored in preclinical studies of Ph+ ALL.20 In one study, the 
combination of venetoclax with various TKIs resulted in synergistic in vitro inhibition of cell growth 
and induction of apoptosis. While this synergy was seen across a number of TKIs tested, this 
effect was most pronounced when venetoclax was combined with either dasatinib or ponatinib. 
The synergistic inhibition of leukemic growth was likely mediated by the ability of these two TKIs 
to target the Lck/Yes novel (LYN) tyrosine kinase in addition to ABL. Combination of venetoclax 
with an inhibitor of LYN resulted in increased expression of the pro-apoptotic BCL-2-like protein 
11 (BIM) and lower expression of the anti-apoptotic myeloid cell leukemia 1 (MCL-1). In a patient- 
derived xenograft ALL mouse model, the combination of a LYN-targeting TKI and ponatinib 
appeared to prevent the increase in MCL-1 with venetoclax treatment, which is an established 
mechanism of venetoclax resistance. These findings provide a strong rational for the 
combination of venetoclax with ponatinib, a potent anti-BCR-ABL1 kinase inhibitor that also 
targets the LYN tyrosine kinase. This combination approach can also test the hypothesis that 
inhibition of LYN by ponatinib can alter the balance of apoptotic proteins in favor of a profile that 
increases leukemia cells’ sensitivity to BCL-2-targeted therapies. 
Summary: There is an unmet need for novel treatment strategies for patients with relapsed or 
refractory Ph+ ALL. Ponatinib is a potent anti-BCR-ABL1 TKI capable of inducing deep and long- 
term remissions when combined with chemotherapy in patients with newly diagnosed Ph+ ALL. 
Venetoclax also shows promise in the treatment of a number of leukemias and other hematologic 
malignancies that are dependent on the anti-apoptotic protein BCL-2 for survival. Furthermore, 
preclinical data suggest that the combination of ponatinib and venetoclax may have synergistic 
effect in Ph+ ALL, mediated through the targeting of the LYN tyrosine kinase. Taken together, 
these preclinical and clinical studies provide a strong rationale for a phase I/II trial combining 
venetoclax with ponatinib in patients with relapsed/refractory Ph+ ALL. 
 
2. 
STUDY OBJECTIVES AND ENDPOINTS 
 
2.1. Primary Objectives 


2017-0313 
August 11, 2020 
Version 4 
5 
 
 
• 
Phase I: To determine the maximum tolerated dose (MTD) of venetoclax, ponatinib 
and dexamethasone in patients with relapsed/refractory Ph+ ALL or lymphoid BP- 
CML 
• 
Phase II: To determine the efficacy of the regimen, as defined by the rate of complete 
remission (CR) or CR with incomplete count recovery (CRi) 
2.2 
Secondary Objectives 
• 
To determine efficacy outcomes, including rate of minimal residual disease negativity 
by PCR for BCR-ABL1 transcripts, median relapse-free survival, and median overall 
survival 
• 
To determine the proportion of patients proceeding to allogeneic stem cell transplant 
(ASCT) 
• 
To preliminarily determine the safety of the combination regimen 
2.3 
Exploratory Objectives 
• 
To evaluate the effect of single-agent ponatinib on apoptotic proteins and Bcl-2 
dependency 
• 
To correlate apoptotic protein expression and Bcl-2 dependency on response and 
resistance to the combination regimen 
• 
To assess impact of baseline genomics on outcomes with the combination regimen 
 
3. 
SELECTION OF PATIENTS 
 
Patients will be selected from those referred to the Leukemia department at M D Anderson 
Cancer Center through the normal of process of referral. Eligible patients will be registered after 
the process of consenting on the MD Anderson protocol and data monitoring system. 
3.1 
Inclusion Criteria 
 
1. Patients ≥ 18 years of age with relapsed/refractory Ph+ ALL or lymphoid blast phase 
CML [either t(9;22) and/or BCR-ABL1 positive by fluorescent in situ hybridization or 
polymerase chain reaction], including prior therapy with at least one Bcr-Abl tyrosine 
kinase inhibitor 
2. Performance status ≤3 (ECOG Scale) 
3. Adequate liver and renal function as defined by the following criteria: 
a) Total serum bilirubin < 1.5 x upper limit of normal (ULN), unless due to Gilbert’s 
syndrome, hemolysis or the underlying leukemia approved by the PI 
b) Alanine aminotransferase (ALT) < 1.5 x ULN, unless due to the underlying 
leukemia approved by the PI 
c) Aspartate aminotransferase (AST) < 1.5 x ULN unless due to the underlying 
leukemia approved by the PI 
d) Creatinine clearance ≥30 mL/min 
4. Adequate pancreatic function as defined by the following criteria: 
a) Serum lipase and amylase < 1.5 x ULN 
5. Ability to swallow 
6. Signed informed consent 


2017-0313 
August 11, 2020 
Version 4 
6 
 
 
3.2 
Exclusion Criteria 
 
1. Prior history of treatment with venetoclax. Prior ponatinib is allowed. 
2. Active serious infection not controlled by oral or intravenous antibiotics (e.g. persistent 
fever or lack of improvement despite antimicrobial treatment). 
3. History of acute pancreatitis within 1 year of study or history of chronic pancreatitis 
4. Uncontrolled hypertriglyceridemia (triglycerides > 450mg/dL) 
5. Active secondary malignancy that in the investigator’s opinion will shorten survival to 
less than 1 year. 
6. Active Grade III-V cardiac failure as defined by the New York Heart Association 
Criteria. 
7. Clinically significant, uncontrolled, or active cardiovascular disease, specifically 
including, but not restricted to: 
• 
History of myocardial infarction (MI), stroke, revascularization, unstable angina or 
transient ischemic attack within the past 12 months 
• 
Left ventricular ejection fraction (LVEF) less than lower limit of normal per local 
institutional standards prior to enrollment 
• 
Diagnosed or suspected congenital long QT syndrome 
• 
Any history of clinically significant atrial or ventricular arrhythmias (such as 
uncontrolled artrial fibrillation, ventricular tachycardia, ventricular fibrillation, or 
Torsades de pointes) as determined by the treating physician 
• 
Prolonged QTc interval on pre-entry electrocardiogram (> 480 msec) unless 
corrected after electrolyte replacement 
• 
History of venous thromboembolism including deep venous thrombosis or 
pulmonary embolism within the past 3 months. Patients with a history of catheter 
associated upper extremity venous thromboembolism are not excluded. 
• 
Uncontrolled hypertension (diastolic blood pressure >100mmHg; systolic 
>150mmHg). 
8. Patients currently taking drugs that are generally accepted to have a high risk of 
causing Torsades de Pointes (unless these can be changed to acceptable alternatives) 
9. Received strong or moderate CYP3A inhibitors or inducers within 3 days of study entry 
10. Consumed grapefruit, grapefruit products, Seville oranges, or star fruit within 3 days 
prior to starting venetoclax 
11. Treatment with any investigational antileukemic agents or chemotherapy agents in the 
last 7 days before study entry, unless full recovery from side effects has occurred or 
patient has rapidly progressive disease judged to be life-threatening by the investigator. 
Prior recent treatment with corticosteroids and hydroxyurea is permitted. 
12. Pregnant and lactating women will not be eligible; women of childbearing potential 
should have a negative pregnancy test prior to entering on the study and be willing to 
practice methods of contraception throughout the study period. Women do not have 
childbearing potential if they have had a hysterectomy or are postmenopausal without 
menses for 12 months. In addition, men enrolled on this study should understand the 


2017-0313 
August 11, 2020 
Version 4 
7 
 
 
risks to any sexual partner of childbearing potential and should practice an effective 
method of birth control. Appropriate birth control will be determined by the treating 
physician. 
 
4. 
TREATMENT OF SUBJECTS 
 
4.1. Variations in doses of the study agents or supportive care medications or dose schedules 
other than those suggested below are allowed if deemed to be in the best interest of 
patients. Such changes should be discussed with the principal investigator before they are 
instituted. 
4.2. Treatment Overview – The regimen consists of 4 cycles of induction/consolidation 
followed by up to 2 years of maintenance therapy for responding patients. For patients who 
have not received ponatinib within 2 weeks of the anticipated start date, the first cycle is 35 
days, as single-agent ponatinib will be given for 7 consecutive days, after which venetoclax, 
ponatinib and corticosteroids will be given in combination. For patients who have received 
ponatinib within 2 weeks of the anticipated start date, the first cycle is 28 days, as the 
ponatinib single-agent lead-in will be omitted. For all patients, each consecutive cycle will 
be 28 days. Patients achieving remission will be referred to ASCT at the discretion of the 
treating physician, based on donor availability and suitability for ASCT. Patients will be 
removed from the study and will discontinue venetoclax at the time of ASCT. These 
patients will still be followed for survival analyses. 
4.3 
Cycle 1 (Induction) – Patients who have not received ponatinib within 2 weeks of the 
anticipated start date will receive the following agents: 
• 
Ponatinib 45mg orally daily on days 1-35 
• 
Venetoclax orally in a daily dose escalation schema: 
• 
• 
 
 
 
 
 
 
• 
Dexamethasone 40mg IV/PO on days 8-11 
• 
CNS prophylaxis with methotrexate 12 mg intrathecally (IT) (6 mg via Ommaya 
reservoir) on day 9 (± 3 days) and cytarabine 100 mg IT on day 14 (± 3 days). 
• 
For patients with CD20 expression (≥20% by flow cytometry), rituximab 375 mg/m2 
may be added at the discretion of the treating physician after the maximum dose of 
venetoclax has been reached. Rituximab will be given on day 14 (±3 days) and on 
day 21 (±3 days). 
 
Patients may receive ponatinib monotherapy on days 1-7 as an outpatient. Bone marrow 
will be performed on day 7 (±1 day) for correlative studies but must be prior to the initiation 
of venetoclax. Additional hydroxyurea or corticosteroids are allowed during the 7-day 
ponatinib lead-in after discussion with the PI. 
 
Due to the potential for tumor lysis syndrome (see section 4.6), patients will be hospitalized 
the day prior to initiation of venetoclax and will remain hospitalized until 24 hours after the 
completion of the venetoclax dose escalation (day 12-14, depending on the dose level). 
Patients in both phase I and phase II cohorts will be hospitalized. Hospital stay may be 
Day 8 
Day 9 
Day 10 
Day 11 
Day 12 
Day 13-35 
Dose level -1 
venetoclax 
20 mg 
50 mg 
100 mg 
200 mg 
200 mg 
200 mg 
Dose level 1 
venetoclax 
(STARTING 
DOSE) 
20 mg 
50 mg 
100 mg 
200 mg 
400 mg 
400 mg 
Dose level 2 
venetoclax 
20 mg 
50 mg 
100 mg 
200 mg 
400 mg 
800 mg 


2017-0313 
August 11, 2020 
Version 4 
8 
 
 
prolonged in patients with infections or other issues requiring inpatient stay. The remainder 
of the cycle can be administered as an outpatient. At the end of cycle 1, patients will have 
bone marrow aspirate/biopsy for response assessment. 
 
For patients who have received ponatinib within 2 weeks of the anticipated start date, both 
venetoclax, ponatinib, and dexamethasone will be started on day 1 of the first cycle, and 
the 7-day lead-in of single-agent ponatinib will be omitted. Therefore, all days above will be 
moved forward 7 days, and the cycle will end on day 28. 
 
 
4.3 
Cycles 2-4 (Consolidation) – Patients will receive the following agents: 
• 
Venetoclax orally at the maximum dose used in cycle 1, given daily on days 1-28 
• 
Ponatinib orally daily on days 1-28. The dose of ponatinib will be adjusted according 
to the remission status as indicated by bone marrow assessment after cycle 1. 
o 
Patients who have not received CR/CRi: 45mg daily 
o 
Patients who have achieved CR/CRi but not CMR: 30mg daily 
o 
Patients who have achieved CR/CRi with CMR: 15mg daily 
• 
Dexamethasone 40mg orally daily on days 1-4 
• 
CNS prophylaxis with methotrexate 12 mg IT (6 mg via Ommaya reservoir) on day 2 
(± 3 days) and cytarabine 100 mg IT on day 7 (± 3 days). 
• 
For patients with CD20 expression (≥20% by flow cytometry), rituximab 375 mg/m2 
may be added at the discretion of the treating physician. Up to 2 doses of rituximab 
may be given during each cycle. 
 
All therapy can be administered in the outpatient setting. A total of 8 doses of IT 
chemotherapy are planned for cycles 1-4. A total of 8 doses of rituximab may be given for 
cycles 1-4. Any missed doses of rituximab or IT chemotherapy can be made up in 
subsequent cycles at the discretion of the treating physician. 
4.3 
Cycles 5+ (Maintenance) – Patients will receive the following agents: 
• 
Venetoclax at the maximum dose used in cycle 1, given daily on days 1-28 
• 
Ponatinib orally daily on days 1-28. The dose of ponatinib will be adjusted according 
to the remission status as assessed by the last bone marrow assessment performed. 
o 
Patients who have achieved CR/CRi but not CMR: 30mg daily 
o 
Patients who have achieved CR/CRi with CMR: 15mg daily 
• 
Dexamethasone 40mg orally daily on days 1-4 
All therapy can be administered in the outpatient setting. Up to 24 cycles of maintenance 
will be administered. The study will end 24 months after the last patient is enrolled. 
4.4. General Considerations 
 
• 
Venetoclax must be administered with food 
• 
Prevention of infection 
o 
Prophylactic antibiotics may be given with each course until neutrophil 
recovery to 500/µL or greater 
o 
Suggestions include: Levaquin 500 mg orally daily (or other appropriate 
antibacterial agent); caspofungin or other appropriate antifungal agent; 
valacyclovir 500 mg orally daily or acyclovir 200 mg orally twice daily or other 
appropriate antiviral agent. 
• 
Prevention and treatment of CNS disease 
o 
8 prophylactic IT chemotherapy treatments are recommended. However, if 
the patient has had prior IT therapy, number of IT chemotherapy can be 


2017-0313 
August 11, 2020 
Version 4 
9 
 
 
reduced if thought by the treating physician to be in the best interest of the 
patient after discussion with the PI. 
o 
For patients with active CNS disease, consider methotrexate alternating with 
cytarabine twice weekly until CSF clear; then once weekly for 4 weeks, then 
back to prophylactic schedule. Consider XRT to the base of the skull, 
particularly with cranial nerve root involvement (cranial nerve palsies). 
Modifications to the regimen thought to be necessary for administration of 
XRT are allowed after discussion with the PI. 
• Venetoclax will provided by the Abbvie through the MDACC pharmacy. Ponatinib is 
indicated for the disease setting and will be charged to the patient/insurance. 
4.5. Suggested Standard Dose Reductions/Modifications: 
 
• Venetoclax 
o Moderate and strong CYP3A inducers and inhibitors are discouraged during 
venetoclax administraton. If a patient requires use of CYP3A inducers, use with 
caution. In many instances, such as antifungal prophylaxis with “azole” therapy in 
neutropenic patients, CYP3A inhibitors are required in ALL patients. Venetoclax 
should be administered at 50% dose reduction in the setting of moderate CYP3A 
inhibitors (i.e. isavuconazole, ciprofloxacin, diltiazem), and 75% dose reduction in 
the setting of strong CYP3A inhibitors (i.e. voriconazole), with the exception of 
posaconazole in which dose reduction should be approximately 83% (e.g. dose 
reduction to 70mg if patient would normally be taking 400mg). The venetoclax 
dose reduction should continue for the duration of co-administration. In the event 
the co-administered CYP3A inhibitor is discontinued, the assigned venetoclax 
dose should be resumed 2-3 days after discontinuation. During the venetoclax 
ramp-up, these agents must be held; however, they may be started or resumed 
24 hours after the highest planned dose of venetoclax is given, along with the 
appropriate dose reduction of venetoclax as above. 
o Non-hematological toxicity - If grade 3 or 4 non-hematologic toxicity is 
attributable to venetoclax, dose interruption of venetoclax is required. Patients 
who experience drug-related grade 3 non-hematological toxicity may be given a 
subsequent course one dose level below the previous course, but the patient 
must have recovered to grade ≤1 before start of the next course. If a patient has 
drug-related grade 4 non-hematological toxicity, he/she may receive a 
subsequent course at one reduced dose level after resolution of toxicity to grade 
≤1, only if approved by the PI based on the clinical significance of the toxicity and 
only if patient has had derived a benefit from the therapy. The dose of venetoclax 
can be decreased during a cycle, at the discretion of treating physician and PI, 
for chronic grade 2 non-hematological toxicity. Other dose modifications may be 
considered as clinically indicated with documentation and approval of the PI. The 
dose reduction guidelines for venetoclax are in the table below: 
 
Current Venetoclax 
Dose 
Reduced Dose 
800mg 
400mg 
400mg 
200mg 
200mg 
100mg 
100mg 
50mg 
50mg 
20mg 


2017-0313 
August 11, 2020 
Version 4 
10 
 
 
 
20mg 
Hold venetoclax 
o Hematologic toxicity 
 Dose interruptions or modifications will be made for grade 4 
hematological toxicities unless it is assessed to be due to the underlying 
disease. Patients with baseline neutropenia or those who have 
significant bone marrow involvement may be particularly at high risk. 
 If a subject achieves CRi or has a morphologically leukemia free bone 
marrow after completion a cycle, venetoclax should be interrupted for up 
to 14 days after the last day of the cycle or until recovery of ANC 
>500/μL. 
 If a subject presents with new onset grade 4 during subsequent cycles, 
unless it is thought to be due to the underlying disease, venetoclax 
dosing should be interrupted until ANC recovery to >500/µL. Subsequent 
dosing should be in consultation with the study PI. For the first episode of 
grade 4 hematologic toxicity the dose of venetoclax may be reduced; 
however for subsequent episodes of grade 4 hematologic toxicity (not 
attributed to the underlying disease), the dose of venetoclax should be 
reduced. The dose reduction guidelines for venetoclax are in the table 
above (same as for non-hematologic toxicity). 
• Ponatinib 
o The following table provides dose reduction guidelines for ponatinib 
 
Current Ponatinib Dose 
Reduced Dose 
45mg 
30mg 
30mg 
15mg 
15mg 
Hold ponatinib 
o Hematologic toxicity 
 Cytopenias are common in the patient population studied in this trial. 
Dose modification for ponatinib for hematologic toxicities will be made 
unless attributed to the underlying leukemia, after appropriate dose 
reductions of venetoclax have been made, as above. 
 No dose modifications are required for grade 1-2 hematologic toxicity or 
for grade 3-4 hematologic toxicity attributed to underlying leukemia. 
 For grade 4 hematologic toxicity occurring despite venetoclax dose 
interruption of ≥1 week, ponatinib should be held until recovery of ANC to 
≥1.5 x 109/L and platelets ≥75 x 109/L, and then resumed at one dose 
level reduction. 
o Grade II transaminase elevation 
 Hold until grade I or less. 
 After resolution to grade I or less, ponatinib may be resumed but must be 
reduced by one dose level. 
o Other liver function abnormalities 
 For patients who develop AST or ALT of >=3x ULN and a total bilirubin of 
>2 x ULN with alkaline phosphatase of <2 x ULN while on treatment, 
ponatinib should be discontinued. Investigation of other causes of liver 
abnormalities (e.g. azoles) is recommended. 
o Pancreatitis 


2017-0313 
August 11, 2020 
Version 4 
11 
 
 
 If asymptomatic grade 1-2 lipase elevation, ponatinib may be held or 
dose reduced at the discretion of the PI. If held, it should be dose 
reduced when resumed. 
 If asymptomatic radiologic pancreatitis (grade 2 pancreatitis), 
asymptomatic grade 3-4 lipase elevation, or symptomatic grade 3 
pancreatitis, hold ponatinib until grade 1, then dose reduce by one dose 
level 
 If grade 4, discontinue ponatinib 
o Arterial or venous thrombosis 
 For patients with arterial thrombosis, ponatinib should be discontinued. 
 For patients with pulmonary embolism or lower extremity deep venous 
thrombosis, ponatinib should be dose reduced (one dose level) or 
discontinued. 
 For patients with superficial venous thrombosis or line-associated upper 
extremity deep venous thrombosis, ponatinib may be continued at the 
same dose, although holding dose and/or dose reduction (one dose 
level) can be considered at the discretion of the treating physician 
according to the assessment of the patient’s best interest. 
o Heart failure 
 If grade 1-2, hold ponatinib until resolution then resume at same dose 
 If grade 3, hold ponatinib until grade 1 or resolved, then reduce dose by 
one dose level 
 If grade 4, discontinue ponatinib 
o 
Hemorrhage or fluid retention (edema) 
 If grade 3-4, hold ponatinib until grade I or less, then reduce dose by one 
dose level. 
o 
Grade Ill-IV non-hematological toxicity (excluding specific toxicities listed 
above) attributed to ponatinib: 
 Hold until grade I or less. 
 Ponatinib may be resumed at one dose level reduction after resolution to 
grade I or less, if resolves within 4 weeks of discontinuation. If the same 
grade III-IV toxicity recurs, ponatinib should be discontinued. 
o Major surgery 
 Ponatinib should be held for at least 1 week prior to any planned major 
surgery, as determined by the PI. 
• Dexamethasone 
o Dose should remain at 40mg unless grade 3 or 4 steroid myopathy or other 
significant toxicity occurs. 
o For grade 3 or higher pancreatitis, dexamethasone should be held until resolved 
to grade 1 or less, after which it may be resumed at the same dose. 
o For other grade 3 or 4 toxicities attributed to dexamethasone, dexamethasone 
should be held until resolved to grade 1 or less, after which it may be resumed at 
the same dose or dose reduced (at the discretion of the PI). 
o Dexamethasone is not required to be dose-adjusted for hyperglycemia. 
o If dose reductions of dexamethasone are performed, guidelines are in the table 
below: 
 
Current Dexamethasone Dose 
Reduced Dose 
40mg 
20mg 
20mg 
10mg 
10mg 
Hold dexamethasone 


2017-0313 
August 11, 2020 
Version 4 
12 
 
 
 
o Further reductions beyond what is shown in the table above may be allowed if 
recommended by the treating physician and after discussion with the PI. 
4.6 Prophylaxis and Management of TLS 
 
• 
There is a potential for TLS, especially in those with elevated pretreatment LDH levels, 
elevated leukocyte count, renal dysfunction, and dehydration. To mitigate the risk for 
TLS, subjects will receive tumor lysis prophylaxis, including hydration (e.g., oral, 
intravenous) and treatment with an agent to reduce the uric acid level (e.g., allopurinol, 
rasburicase) prior to and during the inpatient portion of cycle 1. For subjects who had 
dose delay or interruptions, TLS prophylactic measures may need to be implemented 
based on the disease status prior to resuming treatment. TLS prophylaxis must be 
initiated in all such subjects prior to the first venetoclax dose or first new escalated dose. 
• 
Cycle 1 
o 
Hospitalization (required) starting the night before the initial dose of venetoclax 
for cycle 1 and for up until 24 hours after reaching the target dose (day 12-14 for 
patients without recent ponatinib exposure or day 5-7 for patients with recent 
ponatinib exposure, depending on the dose level) 
o 
An oral agent to reduce the uric acid level (e.g., allopurinol or substitute) must be 
initiated prior to first venetoclax dose. Subjects allergic to or otherwise unable to 
receive allopurinol must use another uric acid reducer or rasburicase prior to 
venetoclax dosing. 
o 
Intravenous hydration must be started upon admission (i.e. the day prior to 
initiation of venetoclax) at a rate as clinically appropriate and will continue 
throughout the hospitalization. Urine output must be monitored. Diuretics may be 
used per investigator discretion. 
o 
TLS chemistry tests (calcium, phosphorus, potassium, uric acid, and creatinine) 
on the first day of venetoclax and each day of a new dose within 6 hours (+/-2 
hours prior to venetoclax dosing. TLS chemistries should also be checked 6 
hours after (+/-2 hours) after the first dose or new dose level. 
o 
TLS chemistry test results (calcium, inorganic phosphorus, potassium, uric acid, 
and creatinine) must be reviewed by the investigator in real time and prior to the 
subject's next dose to ensure appropriate subject management. 
o 
If a subject meets criteria for clinically significant laboratory or clinical TLS, no 
additional venetoclax dose should be administered until resolution. 
• 
Cycles 2+ 
o 
If any laboratory changes are noted in cycle 1, and deemed clinically significant 
for TLS by the investigator, no additional venetoclax doses should be 
administered until resolution. TLS prophylaxis may need to be continued with 
subsequent cycles based on the ongoing risk of development of TLS. 
o 
Drug interruption for up to 48 hours following transient chemical changes and 
laboratory TLS may be allowed and will not require a dose reduction. If the TLS 
has not resolved within 48 hours, then the dose should be reduced. 
• 
4.7 Completion of Phase I – The phase I portion will define the DLTs , MTD and RP2D of 
the combination treatment. Dose escalation will proceed in standard ‘3+3’ design (see 
Statistical Methods section). Once the MTD is established (or if the MTD is not reached with 
800 mg of venetoclax), the phase II portion of the study will commence. 
 
• 
4.8 Definition of DLT – 
A DLT will be defined as any of the following adverse events that cannot be considered 
primarily related to the underlying malignancy, or a comorbid condition, occurring: 


2017-0313 
August 11, 2020 
Version 4 
13 
 
 
 
For patients without recent ponatinib exposure, between day 8 and day 35 of 
cycle 1 (with the exception of hematologic toxicity which may be assessed up to 
day 49 of cycle 1) 
 
For patients with recent ponatinib exposure, between day 1 and day 28 of cycle 1 
(with the exception of hematologic toxicity which may be assessed up to day 42 
of cycle 1) 
Any ≥ grade 3 non-hematologic toxicity with the following exceptions: 
• 
Grade 3 alopecia 
• 
Grade 3 nausea, vomiting, diarrhea with electrolyte abnormalities lasting less than 48 
hours that are not clinically significant and that does not require total parenteral 
nutrition (TPN), tube-feeding, or hospitalization 
• 
Infection, unless the infection resulted from unexpectedly complicated by the degree 
or duration of myelosuppression in the absence of persistent leukemia. 
Patients who receive at least a full course of therapy will be considered to be evaluable for 
toxicity/DLT and will not be replaced unless the PI determines that further additional patients 
at that dose level are required for safety purposes. 
Hematologic toxicity will be defined as: 
• 
For patients without recent ponatinib exposure, failure to recover ANC > 500/µL 
or platelet count > 25,000/µL by day 49. 
• 
For patients with recent ponatinib exposure, failure to recover ANC > 500/µL or 
platelet count > 25,000/µL by day 42. 
This will be considered DLT. For patients with > 5% blasts, myelodysplastic changes, or 
evidence of disease by flow cytometry/cytogenetics, failure to recover neutrophil or 
platelet count may not be considered DLT as this could be the result of persistent 
disease. 
5. 
CONCOMITANT MEDICATIONS 
 
Short-acting antacid agents may be taken, but it is recommended that these not be taken from 2 
hours before to 2 hours after dosing of ponatinib. Proton pump inhibitors may be administered 
concomitantly with ponatinib if felt to be in the patient’s best interest. 
Patients currently taking drugs that are generally accepted to have a risk of causing Torsades de 
Pointes (including: quinidine, procainamide, disopyramide, amiodarone, sotalol, ibutilide, 
dofetilide, erythromycins, clarithromycin, chlorpromazine, haloperidol, mesoridazine, thioridazine, 
pimozide, cisapride, bepridil, droperidol, methadone, arsenic, chloroquine, domperidone, 
halofantrine, levomethadyl, pentamidine, sparfloxacin, lidoflazine) should change these to 
acceptable alternatives, if possible. 
 
General guidelines regarding excluded and cautionary medications are summarized in Table 1 
below. 
 
Table 1. Excluded and Cautionary Medications 


2017-0313 
August 11, 2020 
Version 4 
14 
 
 
 
Excluded 
Anticancer therapies including chemotherapy or other investigational therapy, including targeted 
small molecule agents: Excluded 5 half-lives prior to first dose and throughout venetoclax 
administration 
Biologic agents (e.g., monoclonal antibodies) for anti-neoplastic intent: Excluded 30 days or 5 half- 
lives (whichever is shorter) prior to first dose and throughout venetoclax administration. Rituximab given 
as part of this treatment protocol is an exception. 
Grapefruit and grapefruit products 
Seville Oranges (including marmalade containing Seville oranges) 
Starfruit 
Cautionary 
Warfarin and coumarin derivatives 
P-gp substrates 
BCRP substrates 
OATP1B1/1B3 substrates 
P-gp inhibitors 
BCRP inhibitors 
Strong and Moderate CYP3A inhibitors 
Strong and Moderate CYP3A inducers 
 
Localized radiation is allowed if deemed in the best interest of the patient and after approval by the PI. 
 
Drugs involving these enzymes and transporters can be found in the following webpage: 
http://medicine.iupui.edu/clinpharm/ddis/main-table/ 
6. 
STUDY PROCEDURES 
 
6.1. Pre-Treatment Evaluation 
 
1. History and physical examination, including height and weight, vital signs (blood 
pressure, respiratory rate, pulse and temperature) and ECOG performance status 
2. Concomitant medication and medical history assessment within 24 hours of first dose 
3. CBC with differential, electrolytes (potassium, calcium, magnesium, phosphorus), LDH, 
uric acid, creatinine, liver function tests (AST, ALT, total bilirubin), lipase, amylase, 
triglycerides, hepatitis B antibodies 
4. Bone marrow aspirate, cytogenetics and PCR for BCR-ABL1. Quick Philadelphia screen 
(FISH) is acceptable. 
5. EKG 
6. Pregnancy test in female patients of appropriate age and menopausal state within 1 week 
of first dose 
7. Echocardiogram or MUGA scan to assess cardiac function 
8. Biomarker studies including CyTOF, BH3 profiling, and next-generation targeted 
sequencing and SNP array (performed on bone marrow and peripheral blood) 
All pretreatment evaluation must be performed within 2 weeks of first dose of the study drug, 
unless otherwise specified as above. 
6.2 Evaluation During Study 


2017-0313 
August 11, 2020 
Version 4 
15 
 
 
1. History and physical examination, including vital signs (blood pressure, respiratory rate, 
pulse and temperature) and ECOG performance status prior to each cycle 
2. Evaluation for toxicity assessment prior to each cycle 
3. Assessment of concomitant medications prior to each cycle. 
4. CBC with differential 1-2 times weekly for cycle 1, then prior to each subsequent cycle 
5. In addition to TLS monitoring during the venetoclax ramp-up period (section 4.6), 
electrolytes (potassium, calcium, magnesium, phosphorus), LDH, uric acid, creatinine, 
liver function tests (AST, ALT, total bilirubin) at least weekly for cycle 1, then prior to each 
subsequent cycle 
6. Amylase and lipase as clinically indicated (e.g. for patients with abdominal pain) 
7. Bone marrow aspiration to be performed cycle 1 on day 7 (± 2 days) in patients without 
recent ponatinib exposure only but must be prior to the initiation of venetoclax, and again 
at day 28 (± 5 days) for patients with recent ponatinib exposure or day 35 (± 5 days) for 
patients without recent ponatinib exposure but must be prior to the beginning of cycle 2. 
Additional bone marrow assessment every 2-3 cycles or as clinically indicated. 
Cytogenetics (unless previously diploid) and PCR for BCR-ABL1 should be sent with 
each bone marrow evaluation. 
8. EKG at baseline, during cycle 3, then every 3 months 
9. Echocardiogram or MUGA during cycle 4 and then every 3 months, and as clinically 
indicated 
10. Biomarker studies including CyTOF (on day 7 ± 2 days of cycle 1 for patients without 
recent ponatinib exposure only, at the end of cycle 1 and at the time of relapse), BH3 
profiling (on day 7 ± 2 days of cycle 1 for patients without recent ponatinib exposure 
only, at the time of relapse). Relapse samples will be collected from bone marrow and 
peripheral blood. 
Failure to collect biomarker studies at any time point due to logistical reasons will not be 
considered a protocol deviation or violation. 
A study visit is a visit to MD Anderson Cancer Center every course. 
 
Pre 
Cycle 1 
Cycle 2 
Cycle 3 
Cycle 4 
Cycles 5+ 
Follow- 
Up 
Informed consent 
X 
History + physical 
X 
X 
X 
X 
X 
X Every cycle 
Vital signs 
X 
X 
X 
X 
X 
X Every cycle 
Performance Status 
X 
Concomitant 
medication 
assessment5 
X 
X 
X 
X 
X 
X Every cycle 
X 
Toxicity (AE) 
assessment 
X 
X 
X 
X 
X Every cycle 
X 
CBC with diff 
X 
X 
X 
X 
X 
X Every cycle 
Electrolytes 
(potassium, calcium, 
magnesium, 
phosphorus), LDH, 
uric acid, creatinine, 
liver function tests 
(AST, ALT, total 
bilirubin), lipase and 
amylase4 
X 
X 
X 
X 
X 
X Every cycle 
Triglycerides 
X 


2017-0313 
August 11, 2020 
Version 4 
16 
 
 
 
Hepatitis B antibodies 
X 
Bone marrow 
aspirate 
X 
X1 
X 
X2 
Pregnancy test (If 
indicated) 
X 
EKG 
X 
X 
X Every 3 
months 
Echocardiogram or 
MUGA 
X 
X 
X Every 3 
months 
CyTOF6 
X 
X3 
BH3 profiling6 
X 
X3 
Next-generation 
sequencing and SNP 
array6 
X 
Survival status and 
subsequent treatment 
X 
1Bone marrow aspiration on day 7 (±1 days) for patients without recent ponatinib exposure only and at 
end of cycle 1 (day 28 [±5 days] for patients with recent ponatinib exposure and day 35 [±5 days] 
for patients without recent ponatinib exposure). 
2After achieving CR/CRi, bone marrow should be performed every 2-3 cycles or as clinically indicated. 
3In patients without recent ponatinib exposure, BH3 profiling will be assessed on days 1 and 7 of cycle 1, 
CyTOF will be assessed on days 1, 7 and 35 of cycle 1. In patients with recent ponatinib exposure, 
BH3 profiling will be assessed on day 1 of cycle 1, CyTOF will be assessed on days 1 and 28 of cycle 
1. CyTOF and BH3 profiling will also be performed at the time of relapse. 
4Amylase and lipase will be checked in all patients at screening. Subsequent amylase and lipase only 
need to be checked as clinically indicated (e.g. for patients with abdominal pain) 
5 Concomitant medication data will not be entered into the case report form (Prometheus); however, 
concomitant medications will be documented in the subject’s electronic medical record. 
6 Biomarker studies will not be captured in the case report form. 
6.3 Follow-up 
 
Thirty days after last dose of the study drugs concomitant medication and AE assessment 
will be recorded. This may be done over the phone with a member of the study staff. 
Patients discontinued from study treatment for any reason other than withdrawal of consent 
for treatment will continue to be assessed for survival. Survival information (i.e. the date and 
cause of death) and subsequent treatment will be collected via telephone calls and/or 
clinical visits every 6 months (+/- 2 months) until death or withdrawal of consent. 
 
7. 
EFFICACY AND SAFETY ASSESSMENTS 
 
7.1. CRITERIA FOR RESPONSE 
 
1. Complete Remission (CR): Normalization of the peripheral blood and bone marrow with 
5% or less blasts in normocellular or hypercellular marrow with a granulocyte count of 1 x 
109/L or above, and platelet count of 100 x 109/L. Complete resolution of all sites of 
extramedullary disease is required for CR. 
2. Complete remission without recovery of counts (CRi): Peripheral blood and marrow 
results as for CR, but with incomplete recover of counts (platelets < 100 x 109/L; 
neutrophils < 1 x 109/L). 
3. Complete cytogenetic response (CCyR): Same as for CR with cytogenetics showing 
diploid karyotype (valid only for patients with abnormal cytogenetics at enrollment) 


2017-0313 
August 11, 2020 
Version 4 
17 
 
 
4. Complete molecular response (CMR): Same as for CR with RT-PCR for BCR-ABL 
<0.01%.21 
5. Major molecular response (MMR): Same as for CR with RT-PCR for BCR-ABL with 3 log 
reduction from baseline (for p190 transcripts) and/or ≤0.1% by the International Scale (for 
p210 transcripts) 
6. Partial Response (PR): As above for CR except for the presence of 6-25% marrow 
blasts. 
7. Progressive Disease (PD): increase of at least 25% in the absolute number of circulating 
or bone marrow blasts or development of extramedullary disease 
8. Relapse Disease: reappearance of blasts in the blood or bone marrow >5% or 
development of extramedullary disease after initial response. 
7.2. EVALUATION OF TOXICITY 
 
1. Toxicities will be graded according to the NCI Common Toxicity Criteria for Adverse 
Event Reporting Version 4.0. The toxicity of the regimen will be monitored continuously 
during the course of the study. 
2. AEs will be recorded in the subject’s source documents from the first dose through 30 
days after the last dose. Serious Adverse Events (SAEs) will be captured from the time of 
the first protocol-specific intervention. The Principal Investigator will sign and date the 
Adverse Event Record (AE logs) per patient after the completion of each course. 
Following signature, the AE logs will be used as source documentation for the adverse 
events for attribution. 
7.3. CRITERIA TO STOP TREATMENT 
 
1. Failure to achieve CR/CRi after 2 cycles of treatment, unless the patient is deemed to be 
deriving clinical benefit (e.g. blast reduction not meeting criteria for CR/CRi) as assessed 
by the treating physician and PI 
2. Unacceptable toxicity judged to be related to therapy by the investigator, as defined by 
the NCI Common Toxicity Criteria (irreversible or prolonged (> 42 days) grade 4 
hematological toxicity or grade 4 non-hematological toxicity thought to be related to 
ponatinib or venetoclax), unless it has been been judged by the treating physician and PI 
that the patient is achieving clinical benefit. 
3. Non-compliance by the patient with protocol requirements or patient's request to be 
removed from the study. 
4. Relapse, defined as >5% bone marrow blasts not attributed to hematopoietic recovery, 
occurring after initial response to therapy 
Patients coming off treatment due to the above issues will continue to be followed for 
survival outcomes. 
7.4 DEFINITION OF STUDY END-POINTS 
1. Relapse-free survival is the time from documented CR/CRi until relapse or death. 
2. Event-free survival is the time from the first day of treatment until any treatment failure 
(lack of response, relapse, or death). 
3. Overall response rate is defined as the percentage of patients achieving CR or CRi 
4. Overall survival is defined as the time from the first day of treatment to time of death 
from any cause. 


2017-0313 
August 11, 2020 
Version 4 
18 
 
 
In the primary analysis, survival will not be censored for stem cell transplant. 
8. REPORTING REQUIREMENTS 
 
Adverse event reporting will be as per the NCI criteria and the MDACC Leukemia Specific 
Adverse Event Recording and Reporting Guidelines (Appendix C). 
The descriptions and grading scales found in the revised NCI Common Terminology Criteria for 
Adverse Events (CTCAE) version 4.0 will be utilized for adverse event reporting. 
(http://ctep.cancer.gov/reporting/ctc.html). 
 
These adverse events will be recorded in the Case Report Form (CRF): 
• 
Any grade adverse event that is possibly, probably, or definitely related to the study 
drug(s) 
• 
All serious adverse events regardless of attribution to the study drug(s) 
• 
Any grade adverse event regardless of attribution to the study drugs(s) that results in any 
dose modification 
Patients will be registered in CORe. Prometheus will be used for data entry and AE capture. 
Baseline events will be recorded in the medical history section of the case report form 
(Prometheus) and will include the terminology event name, grade, and start date of the event. 
Abnormal laboratory values or test results will not be recorded or reported as adverse events 
unless it leads to therapeutic intervention, results in dose modification or interruption, or meets 
the protocol definition of a DLT or SAE. 
AEs will be shared with AbbVie on an annual basis. 
 
Serious Adverse Event Reporting (SAE) for M. D. Anderson-sponsored IND Protocols 
 
An adverse event or suspected adverse reaction is considered “serious” if, in the view of either 
the investigator or the sponsor, it results in any of the following outcomes: 
• 
Death 
• 
A life-threatening adverse drug experience – any adverse experience that places the 
patient, in the view of the initial reporter, at immediate risk of death from the adverse 
experience as it occurred. It does not include an adverse experience that, had it occurred 
in a more severe form, might have caused death. 
• 
Inpatient hospitalization (with the exception of planned hospitalization period for cycle 1) 
or prolongation of existing hospitalization 
• 
A persistent or significant incapacity or substantial disruption of the ability to conduct 
normal life functions. 
• 
A congenital anomaly/birth defect. 
Important medical events that may not result in death, be life-threatening, or require 
hospitalization may be considered a serious adverse drug experience when, based upon 
appropriate medical judgment, they may jeopardize the patient or subject and may require 
medical or surgical intervention to prevent one of the outcomes listed in this definition. Examples 
of such medical events include allergic bronchospasm requiring intensive treatment in an 
emergency room or at home, blood dyscrasias or convulsions that do not result in inpatient 
hospitalization, or the development of drug dependency or drug abuse (21 CFR 312.32). 


2017-0313 
August 11, 2020 
Version 4 
19 
 
 
• 
Important medical events as defined above, may also be considered serious adverse 
events. Any important medical event can and should be reported as an SAE if deemed 
appropriate by the Principal Investigator or the IND Sponsor, IND Office. 
 
All events occurring during the conduct of a protocol and meeting the definition of a SAE 
must be reported to the IRB in accordance with the timeframes and procedures outlined 
in “The University of Texas M. D. Anderson Cancer Center Institutional Review Board 
Policy for Investigators on Reporting Unanticipated Adverse Events for Drugs and 
Devices”. Unless stated otherwise in the protocol, all SAEs, expected or unexpected, 
must be reported to the IND Office, regardless of attribution (within 5 working days of 
knowledge of the event). 
• 
All life-threatening or fatal events, that are unexpected, and related to the study drug, must 
have a written report submitted within 24 hours (next working day) of knowledge of the event 
to the Safety Project Manager in the IND Office. 
• 
Unless otherwise noted, the electronic SAE application (eSAE) will be utilized for safety 
reporting to the IND Office and MDACC IRB. 
 
• 
Serious adverse events will be captured from the time of the first protocol-specific 
intervention, until 30 days after the last dose of drug, unless the participant withdraws 
consent. Serious adverse events must be followed until clinical recovery is complete and 
laboratory tests have returned to baseline, progression of the event has stabilized, or there 
has been acceptable resolution of the event. 
• 
Additionally, any serious adverse events that occur after the 30 day time period that are 
related to the study treatment must be reported to the IND Office. This may include the 
development of a secondary malignancy. 
Adverse event reporting will be as per the NCI criteria and the MDACC Leukemia Specific Adverse Event 
Recording and Reporting Guidelines, located in protocol appendix A. 
• 
An adverse event is the appearance or worsening of any undesirable sign, symptom, or 
medical condition occurring after starting the study drug even if the event is not considered to 
be related to study drug. Medical conditions/diseases present before starting study drug are 
only considered adverse events if they worsen after starting study drug. Abnormal laboratory 
values or test results constitute adverse events only if they induce clinical signs or symptoms, 
are considered clinically significant, or require therapy. 
• 
The investigator (or physician designee) is responsible for verifying and providing source 
documentation for all adverse events and assigning the attribution for all adverse events for 
subjects enrolled. 
Reporting to FDA: 
 
• Serious adverse events will be forwarded to FDA by the IND Sponsor (Safety Project Manager 
IND Office) according to 21 CFR 312.32. 
 
It is the responsibility of the PI and the research team to ensure serious adverse events are 
reported according to the Code of Federal Regulations, Good Clinical Practices, the protocol 
guidelines, the sponsor’s guidelines, and Institutional Review Board policy. 
 
Reporting to Abbvie: 


2017-0313 
August 11, 2020 
Version 4 
20 
 
 
Product Complaints: In addition to compliance with all FDA requirements pursuant to 21 CFR 
211 and 21 CFR 820, Principal Investigator will report to AbbVie within 24 hours any suspected 
quality defect in an AbbVie Product or its AbbVie-provided packaging, labeling, or medical device 
component (collectively, “Product Complaint”). Principal Investigator will report Product 
Complaints that involve an AbbVie Product, whether AbbVie has supplied the AbbVie Product 
used in the Study or not. AbbVie’s contact for reporting Product Complaints shall be 
RD_PQC_QS@abbvie.com 
 
In addition to compliance with all FDA reporting requirements pursuant to 21 C.F.R. § 312, the PI 
shall: 
 
• report to AbbVie all serious adverse events experienced by a study subject receiving an AbbVie 
product within 24 hours of learning of the event regardless of the relationship of the event to the 
AbbVie product. Principal Investigator shall make available to AbbVie promptly such records as 
may be necessary and pertinent to investigate any such event, if specifically requested by 
AbbVie; and in addition, report all non-serious adverse events of tumor lysis syndrome for 
studies involving ABT-199 
 
• copy AbbVie on the submission to the FDA of events meeting the definition of IND safety 
reports at the time of submission to the Agency; and 
 
• notify AbbVie upon any subject receiving an AbbVie Product who becomes pregnant 
 
AbbVie’s contact for reporting serious adverse drug experiences, pregnancy experiences, non- 
serious adverse events of tumor lysis syndrome, and communication of FDA submissions of 
IND safety reports shall be PPDINDPharmacovigilance@abbvie.com 
 
 
9. OUTSIDE PHYSICIAN PARTICIPATION DURING TREATMENT 
 
9.1 MDACC Physician communication with the outside physician is required prior to the patient 
returning to the local physician. This will be documented in the patient record. 
 
9.2 A letter to the local physician outlining the patient's participation in a clinical trial will request 
local physician agreement to supervise the patient's care 
9.3 Protocol required evaluations outside MDACC will be documented by telephone, fax or e- 
mail. Fax and/or e-mail will be dated and signed by the MDACC physician, indicating that 
they have reviewed it. 
 
9.4 Changes in drug dose and/or schedule must be discussed with and approved by the MDACC 
physician investigator, or their representative prior to initiation, and will be documented in the 
patient record. 
9.5 A copy of the informed consent, protocol abstract, treatment schema and evaluation during 
treatment will be provided to the local physician. A copy of the REMS (Risk Evaluation and 
Mitigation Strategy) documentation on ponatinib will also be provided to the local physician. 
 
9.6 Documentation to be provided by the local physician will include drug administration records, 
progress notes, reports of protocol required laboratory and diagnostic studies and 
documentation of any hospitalizations. 


2017-0313 
August 11, 2020 
Version 4 
21 
 
 
9.7 The home physician will be requested to report to the MDACC physician investigator all life 
threatening events within 24 hours of documented occurrence. 
 
 
10. STATISTICAL METHODOLOGY 
This is a single arm, open label, phase I/II study to assess the MTD and the efficacy of the combination 
regimen of venetoclax, ponatinib and corticosteroids in patients with relapsed/refractory Ph+ ALL. 
Phase I: The primary objective is to determine the optimal dosing and schedule of the combination 
regimen. This aim will consist of a phase I trial to determine the maximum tolerated dose (MTD) of 
venetoclax when given in combination with ponatinib and dexamethasone. A standard 3+3 dose 
escalation design will be employed: Two dose levels of venetoclax will be explored. Patients will be 
treated in cohorts of size three to six and the dosage will be escalated if the clinical toxicity is acceptable. 
A dose-limiting toxicity (DLT) is defined in “Definition of DLT” in section 4.8. 
The design is constructed to reduce the chance of escalating the dose when the probability of DLT is 
high, and increase the chance of escalating the dose when the probability of DLT is low. The MTD is 
defined as the highest dose level where a DLT occurs within at most one out of six patients treated. The 
escalation scheme is as follows: 
 
(1) If none of the initial three patients in a cohort experiences a DLT, then a new cohort of three patients 
will be treated at the next higher dose level. 
 
(2) If one of the three patients in a cohort experiences a DLT, then up to three additional patients will be 
treated at the same dose. Escalation will continue if only one of the six patients experiences DLT. 
 
(3) If two or more patients in a cohort experience DLT, then the MTD will have been exceeded, and no 
further dose escalation will occur. The previous dose level will be considered the MTD. 
 
(4) If only three patients were treated at a dose level under consideration as the MTD, then up to three 
additional patients will be accrued. If no more than one of the six patients at that dose level experience a 
DLT, then that dose level will be confirmed as the MTD. If two or more patients in that cohort experience 
DLT, then the previous dose level will be studied in the same fashion. 
 
The MTD is defined as the highest dose studied for which the observed incidence of DLT is less than 
33%. Frequencies of toxicities will be tabulated according to the NCI Common Toxicity Criteria. Patients 
will be continued to be followed for one year for evidence of late toxicity. 
 
 
 
Table 1 below gives the probabilities of dose escalation based on true DLT risk in the 3+3 design. 
 
True DLT rate 
Probability of 
escalation 
10% 
20% 
30% 
40% 
50% 
60% 
70% 
80% 
90% 
0.91 
0.71 
0.49 
0.31 
0.17 
0.08 
0.03 
0.01 
0.001 
A minimum of 6 patients and a maximum of 12 patients will be enrolled to the phase I portion of the trial. 
Phase II: The primary objective is to determine the overall response rate, defined as the rate or CR + CRi 
occurring at the end of 2 cycles of treatment. A total of up to 26 patients will be in the phase II part 
including patients who received the MTD dose level in the phase I portion and those enrolled in the phase 
II portion of the study. The target overall response (OR) rate is 60%. This regimen of the combination 
treatment will be considered worthy of further investigation if it elicits an increase in OR to 60% with 


2017-0313 
August 11, 2020 
Version 4 
22 
 
 
acceptable toxicity. A >15% drug-related grade 4-5 toxicity rate is considered unacceptable. Thus, 
interim monitoring rules, assuming the prior distributions below, were constructed that meet the following 
two conditions, 
1) 
Stop if Prob[p(OR, E) < 0.60 | data] > 0.975, or 
2) 
Stop if Prob[p(TOX, E) > 0.15 | data] > 0.8, 
where p(OR, E) and p(TOX, E) are the true OR and toxicity rates for the combination treatment. The first 
rule provides for stopping the study if the data suggest that it is unlikely (i.e., probability < 2.5%) that OR 
rate of the combination treatment is greater than 0.6. The second condition will stop the study early if 
excessive therapy-related grade 4-5 toxicity (>15%) is highly probable (i.e., probability >80%) for the 
combination treatment. Monitoring for toxicity and futility will not begin until 6 patients have been 
evaluated, and cohort size for future evaluations is 2. 
The monitoring rule for the toxicity rate, based on these assumptions and monitoring conditions above is 
found in Table 2. For example, accrual will cease if 2 or more patients experience toxicities among the 
first 6 patients. Toxicities will be continually monitored and will count towards this stopping rule if they 
occur while the patient is still on study. 
 
Table 2. Stop accrual if there are this many drug-related grade 4-5 toxicities among the number of 
patients evaluated 
# patients evaluated 
# patients with toxicities 
6 
2-6 
8-10 
3-10 
12-16 
4-16 
18-20 
5-20 
22-24 
6-24 
26 
Stop due to maximum sample size 
Monitoring the OR rate, based on the above assumptions and monitoring conditions is found in Table 3. 
For example, accrual will cease if no patients experience an overall response in the first 6 patients 
treated. 
 
Table 3. Stop accrual if there are this many response (i.e., # patients with overall response) among the 
number of patients evaluated 
# patients evaluated 
# patients with overall response 
6 
0 
8 
0-1 
10 
0-2 
12 
0-3 
14 
0-4 
16 
0-5 
18 
0-6 
20 
0-7 
22 
0-8 
24 
0-9 
26 
Stop due to maximum sample size 


2017-0313 
August 11, 2020 
Version 4 
23 
 
 
Multc Lean Desktop (version 2.1.0) was used to generate the toxicity and futility stopping boundaries and 
the operating characteristics table (Table 3). In order to utilize the software for the design, a 60% constant 
rate and beta (1.2, 0.8) priors were assumed for the standard treatment response rate and experimental 
treatment response prior distribution, respectively. In addition, a 15% constant rate and beta (0.3, 1.7) 
priors were assumed for the standard treatment toxicity rate and experimental treatment toxicity prior 
distribution, respectively. 
The probability of stopping the study early if the true OR of the combination treatment was 60% and the 
true toxicity rate was 15% was 39.24%. Probabilities of stopping early for high true toxicity rates (i.e., 
40%) were 98.27% when the true OR was 60% and 99.79% when true OR rate was 30%. 
 
Table 4. Operating characteristics for simultaneous monitoring response and toxicity rates for patients 
treated with combination treatment 
True Toxicity Rate 
True OR 
Prob(stop the trial early) 
0.10 
0.30 
0.9028 
0.40 
0.6445 
0.50 
0.3561 
0.60 
0.2064 
0.70 
0.1688 
0.15 
0.30 
0.9256 
0.40 
0.7278 
0.50 
0.5070 
0.60 
0.3924 
0.70 
0.3636 
0.2 
0.30 
0.9506 
0.40 
0.8193 
0.50 
0.6727 
0.60 
0.5966 
0.70 
0.5775 
0.3 
0.30 
0.9861 
0.40 
0.9490 
0.50 
0.9076 
0.60 
0.8861 
0.70 
0.8808 
0.4 
0.30 
0.9979 
0.40 
0.9922 
0.50 
0.9860 
0.60 
0.9827 
0.70 
0.9819 
 
Secondary objectives include: the rate of minimal residual disease negativity by PCR for BCR-ABL1 
transcripts, proportion of patients proceeding to ASCT, relapse-free survival, overall survival, and the 
safety of the combination regimen. 
 
The investigator is responsible for completing toxicity/efficacy summary reports and submitting them to 
the IND office Medical Affairs and Safety Group for review. These should be submitted as follows: 


2017-0313 
August 11, 2020 
Version 4 
24 
 
 
• 
Phase I: A toxicity summary must be submitted after the first 3 evaluable patients, complete 1 
cycle of study treatment, and every 3 evaluable patients thereafter, IND office approval must be 
obtained prior to advancing/changing dose levels. 
• 
Phase II: A efficacy/toxicity summary must be submitted after the first 6 evaluable patients 
complete the second cycle of study treatment, and every 2 patients thereafter. 
A copy of the cohort summary should be placed in the Investigator’s Regulatory Binder under 
“sponsor correspondence”. 
Analysis Plan: Demographic/clinical characteristics and safety data of the patients will be summarized 
using descriptive statistics such as mean, standard deviation, median and range. 
For the primary efficacy analysis, we will estimate the OR for the combination treatment (defined as the 
proportion of patients achieving CR or CRi after 2 cycles of treatment), along with the 95% credible 
interval. This regimen will be considered worthy of further investigation if an OR rate of at least 60% is 
achieved. Patients who drop out of the study before completing 2 cycles will be treated as “failures” for 
the primary analysis. The association between response and patient’s clinical characteristics such as 
apoptotic protein expression, will be examined by Wilcoxon’s rank sum test or Fisher’s exact test, as 
appropriate. 
The proportion of patient achieving CMR (as assessed by PCR for BCR-ABL transcripts) after 2 cycles of 
therapy will be estimated. The proportion of patients proceeding to ASCT and median time to ASCT will 
also be reported. 
Kaplan-Meier curves will be used to estimate unadjusted OS and RFS distributions. Overall survival 
defined as the time from treatment initiation to death or last follow-up. RFS is defined as the time from the 
date of remission to relapse from CR or death from any cause whichever occurs first. Median OS and 
RFS as well as 1-year OS and RFS rates will be reported. Comparisons of time-to-event endpoints by 
important subgroups will be made using the log-rank tests. 
 
Patients who enrolled in the phase I part of the trial who receive the MTD of venetoclax will be included in 
all efficacy analyses. 
Toxicity type, severity and attribution will be summarized for each patient using frequency tables. 
Sample Size: We will treat up to 26 patients at the recommended phase II dose (including patients who 
received the MTD dose level in the phase I portion and those enrolled in the phase II portion of the study). 
For the efficacy endpoint, with a sample size of 26 patients, If the study is not stopped early and 26 
patients have been treated and evaluated in the study, assuming 16 of the 26 patients achieve OR, then 
the 95% credible interval for OR rate will be (0.43,0.79). 
Approximately 10 patients per year are expected to be enrolled. The total study duration is expected to 
be 5 years (3 years of new patient enrollment, plus an additional 2 years of follow-up). 
 
11. REFERENCES 
1. 
Lee HJ, Thompson JE, Wang ES, Wetzler M. Philadelphia chromosome-positive acute 
lymphoblastic leukemia: current treatment and future perspectives. Cancer 2011;117:1583-94. 
2. 
Gleissner B, Gokbuget N, Bartram CR, et al. Leading prognostic relevance of the BCR-ABL 
translocation in adult acute B-lineage lymphoblastic leukemia: a prospective study of the German 
Multicenter Trial Group and confirmed polymerase chain reaction analysis. Blood 2002;99:1536-43. 
3. 
Fielding AK, Rowe JM, Buck G, et al. UKALLXII/ECOG2993: addition of imatinib to a standard 
treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemia. 
Blood 2014;123:843-50. 


2017-0313 
August 11, 2020 
Version 4 
25 
 
 
4. 
Ravandi F, O'Brien SM, Cortes JE, et al. Long-term follow-up of a phase 2 study of chemotherapy 
plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute 
lymphoblastic leukemia. Cancer 2015;121:4158-64. 
5. 
Jabbour E, Kantarjian H, Ravandi F, et al. Combination of hyper-CVAD with ponatinib as first-line 
therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single- 
centre, phase 2 study. The Lancet Oncology 2015;16:1547-55. 
6. 
Yanada M, Takeuchi J, Sugiura I, et al. High complete remission rate and promising outcome by 
combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic 
leukemia: a phase II study by the Japan Adult Leukemia Study Group. Journal of clinical oncology : 
official journal of the American Society of Clinical Oncology 2006;24:460-6. 
7. 
Thomas DA, Faderl S, Cortes J, et al. Treatment of Philadelphia chromosome-positive acute 
lymphocytic leukemia with hyper-CVAD and imatinib mesylate. Blood 2004;103:4396-407. 
8. 
Martinelli G, Dombret H, Chevallier P, et al. Complete Molecular and Hematologic Response in 
Adult Patients with Relapsed/Refractory (R/R) Philadelphia Chromosome-Positive B-Precursor Acute 
Lymphoblastic Leukemia (ALL) Following Treatment with Blinatumomab: Results from a Phase 2 Single- 
Arm, Multice…. Blood 2015;126:679-. 
9. 
Sanford DS, Kantarjian H, O'Brien S, Jabbour E, Cortes J, Ravandi F. The role of ponatinib in 
Philadelphia chromosome-positive acute lymphoblastic leukemia. Expert review of anticancer therapy 
2015;15:365-73. 
10. 
Cortes JE, Kim DW, Pinilla-Ibarz J, et al. A phase 2 trial of ponatinib in Philadelphia chromosome- 
positive leukemias. The New England journal of medicine 2013;369:1783-96. 
11. 
Sasaki K, Jabbour EJ, Ravandi F, et al. Hyper-CVAD plus ponatinib versus hyper-CVAD plus 
dasatinib as frontline therapy for patients with Philadelphia chromosome-positive acute lymphoblastic 
leukemia: A propensity score analysis. 2016. 
12. 
Konopleva M, Pollyea DA, Potluri J, et al. A Phase 2 Study of ABT-199 (GDC-0199) in Patients 
with Acute Myelogenous Leukemia (AML). Blood 2014;124:118-. 
13. 
Roberts AW, Davids MS, Pagel JM, et al. Targeting BCL2 with Venetoclax in Relapsed Chronic 
Lymphocytic Leukemia. The New England journal of medicine 2016;374:311-22. 
14. 
Konopleva M, Pollyea DA, Potluri J, et al. Efficacy and Biological Correlates of Response in a 
Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia. Cancer 
discovery 2016;6:1106-17. 
15. 
Wei A, Strickland SA, Roboz GJ, et al. Safety and Efficacy of Venetoclax Plus Low-Dose 
Cytarabine in Treatment-Naive Patients Aged ≥65 Years with Acute Myeloid Leukemia. Blood 
2016;128:102-. 
16. 
Anderson MA, Huang D, Roberts A. Targeting BCL2 for the treatment of lymphoid malignancies. 
Seminars in hematology 2014;51:219-27. 
17. 
Geng H, Brennan S, Milne TA, et al. Integrative epigenomic analysis identifies biomarkers and 
therapeutic targets in adult B-acute lymphoblastic leukemia. Cancer Discov 2012;2:1004-23. 
18. 
Alford SE, Kothari A, Loeff FC, et al. BH3 Inhibitor Sensitivity and Bcl-2 Dependence in Primary 
Acute Lymphoblastic Leukemia Cells. Cancer Res 2015;75:1366-75. 
19. 
Scherr M, Elder A, Battmer K, Barzan D, Bomken S. Differential expression of miR-17~92 
identifies BCL2 as a therapeutic target in BCR-ABL-positive B-lineage acute lymphoblastic leukemia. 
Leukemia 2014;28:554-65. 
20. 
Leonard JT, Rowley JS, Eide CA, et al. Targeting BCL-2 and ABL/LYN in Philadelphia 
chromosome-positive acute lymphoblastic leukemia. Science translational medicine 2016;8:354ra114. 
21. 
Short NJ, Jabbour E, Sasaki K, et al. Impact of complete molecular response on survival in 
patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 2016;128:504-7.